RET and neoplasm: Given the rarity of ALK translocations in salivary duct cancers there will not be any trial or FDA approval short of a tumor agnostic approval, which the FDA has recently approved for other oncogenic aberrations (i.e., BRAF V600E, NTRK, RET, among others)21.